Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

Key Points

Recurrent limb events, cardiovascular events, and all-cause mortality were significantly lower with GLP-1 RAs.
Treatment with GLP-1 receptor agonists led to reduced risks over DPP-4 inhibitors in a high-risk group.
Cohort analysis of patients with diabetes previously experiencing major adverse limb events.
Findings support prioritizing GLP-1 RA use for better outcomes in this population.

Abstract

In this nationwide cohort study of patients with diabetes and prior MALEs, treatment with GLP-1 RAs was associated with significantly lower risks of recurrent limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared with DPP-4 inhibitors. These findings support the preferential use of GLP-1 RAs for secondary prevention in this high-risk population.

Bookmark

View Full Paper

Bookmark

View Full Paper

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

Key Points

Abstract

Cite This Study